

TRENDS BOX

- Metabolic intermediates of biochemical pathways are able to act as intra- and extracellular signalling molecules affecting immune cell responses.
- The signalling effects of metabolites are concentration and localization dependent.
- Their functions go beyond self-regulatory mechanisms and include cell to cell communication as well as sensing of micro-environmental conditions to elicit stress responses and cellular adaptation.

1 **Intermediates of metabolism: from bystanders to signalling molecules**

2

3 Robert Haas^{1*}, Danilo Cucchi^{1,2*}, Joanne Smith^{1*}, Valentina Pucino^{1,3}, Claire Elizabeth Macdougall¹

4 and Claudio Mauro^{1#}

5

6 ¹ William Harvey Research Institute, Barts and The London School of Medicine and Dentistry,

7 London, UK

8 ² Istituto Pasteur, Fondazione Cenci Bolognetti, Rome, Italy

9 ³Department of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy

10 * Equal contribution

11 # c.mauro@gmul.ac.uk

12

13 Keywords: glycolysis, tricarboxylic acid cycle, fatty acid oxidation, lactate, succinate

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

14 **Summary**

15

16 The integration of biochemistry into immune cell biology has immensely contributed to our
17 understanding of immune cell function and the associated pathologies. So far, most studies have
18 focused on the regulation of metabolic pathways during an immune response and their contribution
19 to its success. More recently, novel signalling functions of metabolic intermediates are being
20 discovered that might play important roles in the regulation of immunity. Here, we describe the
21 three long-known small metabolites lactate, acetyl-CoA and succinate in the context of immuno-
22 metabolic signalling. Functions of these ubiquitous molecules are largely dependent on their intra-
23 and extra-cellular concentrations as well as their sub-compartmental localization. Importantly, the
24 signalling functions of these metabolic intermediates extend beyond self-regulatory roles and
25 include cell to cell communication and sensing of micro-environmental conditions to elicit stress
26 responses and cellular adaptation.

27

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

28 **Metabolite signaling in immunity**

29

30 The metabolic regulation of immune cells during health and disease has gained a lot of
31 attention as the active reconfiguration of immune cell metabolism enables these cells to sustain
32 certain effector functions. The focus so far has been on the necessity of the main catabolic pathways
33 glycolysis, fatty acid oxidation, the anaplerotic tricarboxylic acid (TCA) cycle and oxidative
34 phosphorylation as well as amino acid metabolism (Figure 1) during activation, proliferation,
35 differentiation and function as a response to extracellular signals.

36 It is now becoming increasingly evident that small molecule intermediates of these
37 metabolic pathways, besides their anabolic and catabolic function, can act as intra- and extracellular
38 signals that influence the outcome of an immune response. The roles of metabolite signalling stretch
39 from regulation of cytokine production via indirect effects on the cellular redox state [1] or direct
40 interaction with transcription factors binding the specific cytokine promoter elements [2] and
41 modulating the activity of transmembrane ion channels [3], to interference with cell migration and
42 differentiation. Interestingly, a few G-protein coupled receptors that are activated by intermediates
43 of metabolism have recently been identified supporting a role for metabolites as extracellular signals
44 [4, 5]. In this review, we discuss the three well known metabolites lactate, succinate and acetyl-CoA
45 in more detail; identify their differences and similarities in signal transduction and effect on
46 immunity and inflammation that defines them as novel signalling molecules in physiology and
47 pathology.

48

49 **Lactate is a signalling molecule**

50

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
51 Lactate is a ubiquitous molecule, whose presence in the mammalian body was first observed
52 in muscle tissue at the beginning of the 19th century [6]. Since its discovery, lactate has been
53 intensely studied and it has been shown to have numerous metabolic functions (Figure 2, Key
54 Figure), including as a central metabolite in the Cori cycle (also known as the lactic acid cycle), which
55 mediates metabolic cross talk between the liver and the muscle. In the Cori cycle, muscle tissue
56 metabolizes liver-derived glucose to lactate, which in turn is shuttled back to the liver and acts as a
57 fuel source for hepatic gluconeogenesis [7]. By contrast, in the brain lactate acts as a metabolic
58 signal and fuel for oxidative metabolism, which is the basis of the neuron-astrocyte lactate shuttle
59 [8]. Briefly, the neurotransmitter glutamate induces high glycolytic activity in astrocytes, which
60 secrete lactate into the synaptic cleft. The increased availability of extracellular lactate enables
61 neurons to import it and use it as an alternative fuel source.

26
27
28
29
30
31
32
62 Although lactate has been known to biochemists for over two hundred years, it has been
63 long neglected, seen as a by-product or a bio-marker at best rather than a bio-active molecule. As a
64 consequence its potential functional effects have been under appreciated.

33
34
35
36
37
38
39
40
41
42
43
44
65 Recently, lactate is being rediscovered as an active signalling metabolite in multiple fields of
66 biology and medicine that has two main ways of signal transduction – transporter and receptor
67 mediated. Its direct regulation of global gene transcription [9, 10], endothelial and cancer cell
68 migration [11, 12], cancer progression [13] and functional polarization of immune cells are being
69 described [14-16].

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
70 Lactate production occurs mainly in the cytoplasm during hypoxia or aerobic glycolysis in
71 proliferative cells and is then secreted through the plasma membrane. This transport is dependent
72 on six so far described solute carrier transporters that perform proton – lactate symport (Mct1-4) or
73 a sodium-dependent symport (Slc5a8, Slc5a12) [17, 18]. The MCT family harbours 14 members that
74 all share conserved sequence motifs, yet differ in their substrate specificity, transport rate and
75 expression pattern [17]. Indeed, only Mct1 (Slc16a1, Km 4.5) and Mct4 (Slc16a3, Km 28) have been
76 shown to have a high specificity for lactate in concord with broad tissue expression [17, 19].

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

77 Similarly, sodium-coupled lactate transport is carried out by the ubiquitously expressed high affinity
78 transporter Slc5a8 or the low affinity transporter Slc5a12 [18]. The transport direction of both
79 systems depends on the intra- and extracellular concentration of lactate, favouring lactate import
80 (even through low affinity transporters) only in the presence of high extracellular lactate
81 concentrations.

82 The physiological lactate concentration is about 1.5mM – 3mM [18] in blood and healthy
83 tissues, but can rise up to 10mM in inflammatory pathologies such as atherosclerotic plaques or
84 rheumatic synovial fluid and even up to 20-30mM in cancerous tissue [14, 15, 20]. Far from being
85 inert, accumulating lactate – a feature of most inflammatory sites – has tremendous effects on
86 tissue resident or infiltrating immune cells as well as stromal cells. In the tumour microenvironment,
87 lactate produced by tumour cells is taken up by macrophages where it promotes polarization
88 towards Arginase 2 (Arg2) expressing M2-like phenotype via Hypoxia inducible factor 1 α (Hif-1 α)
89 stabilization and the resulting increased production of vascular endothelial growth factor (VEGF).
90 These effects further enhance tumour growth in a vicious loop [14]. The authors applied unbiased
91 high-throughput platforms to look for hypothetical protein factors perpetuating such vicious loop,
92 but surprisingly found lactate as the orchestrating factor. Similarly, an independent study recently
93 found lactate to be the driving force behind tumour associated macrophage (TAM) development
94 during epithelial to mesenchymal transition [16].

95 The involvement of Hif-1 α in the response to lactate is currently under scrutiny. On the one
96 hand, it has been demonstrated that targeting the lactate transporter Mct1 in endothelial cells or
97 cervix squamous carcinoma cells rescues lactate-mediated Hif-1 α activation and inhibits the
98 consequential angiogenesis [21, 22]. On the other hand, these authors could show a lactate
99 mediated Hif-1 α independent induction of angiogenesis. Here, reactive oxygen species (ROS)
100 induced the NF- κ B pathway that led to IL-8 expression, a known chemotactic molecule that resulted
101 in increased cell migration and tumour metastasis [23]. Additionally, a recent study demonstrates
102 the Hif-1 α independent, direct binding of lactate to NDRG3 during hypoxia. Upon lactate binding,

103 NDRG3 is stabilized and executes a Raf-ERK1/2 mediated signalling cascade promoting angiogenesis
104 and cell growth [24]. Surprisingly, not only migration-promoting but also inhibiting functions of
105 lactate have been described.

106 Activated T cells that infiltrate inflammatory sites are exposed to the increased lactate
107 concentration that is commonly found in these sites (e.g., 10-12mM in arthritic synovium) [15]. Due
108 to the high extracellular concentration, lactate internalization through the CD8⁺ T cell specific
109 transporter Mct1 and CD4⁺ T cell specific transporter Slc5a12 is favoured. This inhibits glycolysis via
110 inhibition of Pfk or downregulation of Hk1 [15, 25], causing T cells to lose their responsiveness to
111 chemokines and effectively trapping them in the inflamed site. Of note, these effects are not only
112 observed in *in vitro* assays; in an animal model of peritonitis, lactate levels and T cell numbers in the
113 peritoneum are indeed increased 5 days after intra peritoneal (i.p.) injection with zymosan, a glucan
114 commonly used to induce sterile inflammation. Of note, inhibition of lactate transporters re-
115 establishes T cell migration not only *in vitro* but also in the peritonitis model [15]. These findings
116 describe a mechanism explaining at least in part the well-known clinical observation that T cells are
117 entrapped in inflamed tissue [15] (Figure 2).

118 In addition, lactate also triggers the production of the pro-inflammatory cytokine IL-17 in the
119 CD4⁺ subset and inhibits the cytolytic function of cytotoxic CD8⁺ T cells (CTL) (Figure 2). The observed
120 inhibition of CTL function was also reported in an earlier publication, showing that both proliferation
121 and cytokine production in human CTLs is severely impaired in the presence of lactic acid [26].

122 The observed effects of T cell entrapment, CTL inhibition and increased production of pro-
123 inflammatory cytokines are common features of many chronic inflammatory diseases that might be
124 in part explained by lactate signalling. The detailed molecular mechanisms for lactate mediated
125 inhibition of T cell migration and change in function, however, are yet to be elucidated.

126

127 Interestingly, the above effects of lactate/lactic acid on macrophages, endothelial cells and T
128 cells are independent of the pH change that is caused by the acidic form of lactate [15, 16], yet
129 protons are still required for the translocation of lactate into the cytoplasm [15].

130 Additional evidence establishing lactate as a signalling molecule comes from the
131 identification of the lactate receptor Gpr81, first cloned in 2001 [27]. Seven years later, lactate was
132 identified as the primary ligand for Gpr81, being involved in lactate-mediated reduction of lipolysis
133 in adipocytes, the primary Gpr81-expressing cell type [4]. It is now known that Gpr81 is a G-protein
134 coupled receptor that inhibits adenylyl cyclase via the Gi signalling pathway [28] and mediates the
135 insulin-induced reduction of lipolysis [29, 30]. Interestingly, several reports identify lactate receptor
136 activation as a critical survival signal for cancer cells [31, 32], and define it as a therapeutic target in
137 ischemic brain injury [33] (Figure 2).

138 In contrast to the roles of lactate on cell signalling, its effect on regulating other metabolic
139 pathways is better understood. Once in the cytoplasm, lactate is readily oxidized to pyruvate by
140 lactate dehydrogenase (LDH). This reaction proceeds with a concomitant proton transfer from
141 lactate to nicotinamide dinucleotide (NAD⁺) thereby generating NADH and affecting the redox state
142 of the cell (see Glossary). Although LDH is mainly considered a cytoplasmic enzyme, after years of
143 controversy the existence of a mitochondrial LDH has finally been proven [34]. Thus, given the
144 presence of Mct1 in the mitochondrial membrane [35], lactate metabolism is now being considered
145 as an active part of mitochondrial metabolism. Recently, the LDH subunit B (LDHB) has also been
146 shown to localize to peroxisomes in fibroblasts and HeLa cells [36]. This might be a hint towards the
147 possible involvement of lactate in fatty acid oxidation or lipid metabolism in general as discussed in
148 the following excellent review [37].

149 Contrarily, the effects on glycolysis remain questionable. It was shown that 10mM
150 extracellular lactate inhibits glycolytic activity in T cells, which could be facilitated by downregulation
151 of hexokinase 1 or direct inhibition of phosphofructokinase. By contrast, in heart tissue lactate

152 causes increased Glut1 and Glut4 expression on the plasma membrane, which is in general an
153 indicator of increased glucose uptake and flux [38].

154 Taken together, lactate-induced signalling is an important pathway in health and disease. As
155 discussed here, lactate has two primary means of relaying signals into the cell (receptor- and
156 transporter-mediated), and lactate signalling has several possible outcomes that depend on the cell
157 type. Moreover, the concentration of extracellular lactate that lie between 1.5mM in physiological
158 and 10-30mM in pathological settings has immense impact on cell function as it will lead to the
159 activation of different signalling pathways.

161 **Effects beyond metabolism of TCA cycle intermediates: focus on succinate**

162
163 It is now becoming clear that the reaction intermediates of the TCA cycle (Figure 1; Box 1)
164 can act as proper signalling molecules once they are withdrawn from the cycle and redirected
165 towards different functions. This occurs both in physiological and pathological conditions; for
166 instance, citrate accumulates in the cytosol of Lipopolysaccharide (LPS) -treated macrophages where
167 it is necessary for the synthesis of NO, ROS and prostaglandins [39]. Fumarate has been recently
168 defined as a proto-oncometabolite [40, 41] because its accumulation, due to loss of function
169 mutations in the fumarate hydratase (FH) (see Glossary) [42, 43], results in stabilization of Hif-1 α via
170 two different mechanisms: the inhibition of PHD2 (prolyl hydroxylase domain-containing protein 2),
171 which targets HIF factors for degradation [44], and the amplification of ROS signalling through the
172 consumption of reduced glutathione and NADPH [41]. Another TCA cycle metabolite that can
173 regulate non-metabolic activities is NAD⁺, an important cofactor for sirtuins, a family of deacetylases
174 that targets important transcription factors of the inflammatory response, such as NF-kB [45] and
175 AP1 [46], and controls mitochondrial quality and biogenesis [47].

176 For the rest of this section we focus on succinate, as in the past few years it has been
177 reported to be a central metabolite in the biology of immune cells (such as macrophages) as well as

178 in cancer and other pathological contexts, providing a clear example of a new potential therapeutic
179 target.

180 Succinate is synthesized from α -ketoglutarate (first converted to succinyl-CoA and then to
181 succinate) and subsequently utilized as a substrate by succinate dehydrogenase (SDH) to produce
182 fumarate (Figure 3). Inhibition of SDH results in accumulation of succinate, stabilization of Hif-1 α ,
183 induction of Hif-1 α transcriptional activity and oncogenic events. Stabilization of Hif-1 α is due to the
184 ability of succinate to inhibit PHD enzymes (prolyl hydroxylases). Hydroxylation of HIF by PHD
185 enzymes is necessary for its binding to pVHL, part of an E3 ubiquitin ligase targeting HIF for
186 degradation [48]. Thus, reduction of this hydroxylation results in HIF stabilization leading to the
187 transcription of genes involved in proliferation, angiogenesis and metastasis [49] (Figure 3).

188 Stabilization of Hif-1 α by succinate was also observed in LPS-treated macrophages and was
189 associated with enhanced production of IL-1 β [2]. The authors observed an accumulation of
190 succinate in macrophages after Toll-like receptor 4 (TLR4) engagement by LPS, which was
191 responsible for the stabilization of Hif-1 α . The stabilization of Hif-1 α in activated macrophages was
192 directly linked to the increased transcription and production of IL-1 β ; indeed, the authors
193 demonstrated that Hif-1 α can bind the promoter of IL-1 β , activating its transcription. LPS-treated
194 macrophages undergo a switch from oxidative phosphorylation to glycolysis, lowering the activity of
195 the TCA cycle, which raises questions as to the source of succinate accumulation. Indeed, the main
196 source of succinate after LPS treatment appears to be glutamine, mainly via anaplerosis of α -
197 ketoglutarate feeding into the TCA cycle and replenishing succinate, and, to a lesser extent, via the
198 GABA (γ -aminobutyric acid) shunt (Figure 3). These findings suggest succinate is an inflammatory
199 signal that is necessary to activate macrophages and stabilize a fundamental player of immune
200 response, Hif-1 α , leading to the production of IL-1 β [2] (Figure 3).

201 A new depth of understanding of the metabolic rewiring of intracellular metabolism was
202 obtained by a study that used metabolomics and transcriptomics to characterize, in detail, the
203 changes that occur in macrophages during polarization towards M1 or M2 phenotypes [50]. With

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

204 regard to M1 polarization, they identified two TCA cycle break-points: the first at the conversion
205 point of citrate to α -ketoglutarate, and the second after succinate synthesis at the conversion point
206 of succinate to fumarate. The first break-point, due to the downregulation of isocitrate
207 dehydrogenase, results in citrate accumulation, which is then redirected towards production of
208 itaconic acid, an anti-microbial metabolite [51]. The authors also described a second break-point, at
209 the TCA step of converting succinate into fumarate; succinate accumulation increased, as previously
210 reported [2]. Despite the low efficiency of succinate to fumarate conversion, an accumulation of
211 malate (produced from fumarate) was also observed. This was due to the upregulation of the
212 arginosuccinate shunt, a series of reactions feeding first into fumarate and then malate. This shunt is
213 important not only to replenish malate and subsequently citrate (to complete the cycle) but also to
214 produce NO and IL-6, both necessary for appropriate activation of macrophages [50].

215 Ischaemia reperfusion (IR) also causes the specific accumulation of succinate and
216 subsequent production of mitochondrial ROS. Production of ROS during ischaemia reperfusion has
217 always been thought to be a nonspecific response due to reperfusion; however, a recent study
218 demonstrates that succinate accumulation during reperfusion of ischaemic tissues is a selective
219 response that drives the generation of ROS responsible for tissue damage [52]. Using an *in vivo*
220 model of ischaemia in combination with unsupervised metabolomics analysis, succinate was found
221 to specifically accumulate during ischaemia in different tissues (liver, kidney, heart and brain) and it
222 was rapidly re-oxidized during reperfusion. To assess the source of succinate, they performed stable
223 isotope tracing experiments and found that succinate derived mainly from the malate/aspartate
224 shuttle (MAS) and the purine nucleotide cycle (PNC) (Figure 3). These two pathways led to the
225 accumulation of fumarate which was then converted to succinate by the reversal of SDH. During
226 reperfusion the accumulated succinate was rapidly re-oxidized to fumarate by SDH, leading to a
227 massive production of mROS, mainly superoxide (Figure 3), due to the reverse electron transport
228 (RET) through mitochondrial complex I (see Box 1) [52]. This observation describes succinate as a
229 damage signal during reperfusion, making it an intriguing target for therapy development.

230 In addition to these intracellular non-metabolic effects of succinate, it also binds to a specific
1
2 231 receptor localized onto the cytoplasmic membrane, which suggests it can signal as an extracellular
3
4 232 molecule (Figure 3). The succinate receptor, GPR91 (also known as SUCNR), is a G protein-coupled
5
6
7 233 receptor whose activation triggers intracellular calcium release and inhibits cAMP production. In
8
9 234 mouse, it is expressed mainly in the kidney, liver, spleen and small intestine [5]. GPR91 is expressed
10
11 235 on human and mouse dendritic cells (DC), where it enhances their immune-stimulatory capacity
12
13 236 [53]. Specifically, succinate stimulation of GPR91 promotes migration of DC in a dose-dependent
14
15 237 manner, and it cooperates with TLR ligands to induce cytokines via Erk1/2 phosphorylation.
16
17 238 Furthermore, succinate sustains and empowers DC-mediated T cell activation. These effects were
18
19 239 shown to be dependent on succinate stimulation of GPR91, as they were abrogated in *Sucnr*^{-/-} mice
20
21 240 [53].
22
23
24
25
26 241

242 **Immune regulation by fatty acid oxidation: in search of a signalling role for lipid intermediates**

29
30
31 243

32
33 244 Unlike glycolysis and the TCA cycle, the intermediates of fatty acid metabolism have not yet
34
35 245 been shown to regulate T cell fate and functional specification (Figure 1 and Box 1). However, both
36
37 246 the induction of fatty acid synthesis (FAS) and its inverse metabolic pathway, fatty acid oxidation
38
39 247 (FAO), have been linked to T cell function. Specifically, while the induction FAS is known to be an
40
41 248 integral part of the T cell activation program that is associated with increased glucose metabolism,
42
43 249 which is essential for the differentiation of naïve T cells into their T effector subsets, FAO has been
44
45 250 shown to be critical for the development of CD8⁺ memory T cells and the induction of CD4⁺
46
47 251 regulatory T cells [54, 55] (Figure 4).
48
49
50
51

52 252 Mice with a T cell-specific deletion of tumour necrosis factor (TNF) receptor-associated
53
54 253 factor 6 (TRAF6) displayed a profound defect in CD8⁺ memory T cell generation, and were unable to
55
56 254 upregulate FAO after growth factors withdrawal during contraction phase of immune response.
57
58 255 TRAF6-deficient CD8⁺ T cells exhibited defective AMP-activated kinase (AMPK) activation, whereas
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

256 activation of AMPK with metformin was able to rescue both FAO and the generation of CD8⁺
257 memory T cells, suggesting TRAF6 regulates a metabolic switch towards FAO important for
258 generation of long-lived CD8⁺ memory T cells [54]. Regulatory CD4⁺ T cells (Tregs) have also been
259 shown to rely primarily on FAO during their development [55, 56]. Naturally occurring Tregs display
260 low levels of Glut1, and thus low rates of glycolysis, while having increased activation of AMPK.
261 Treatment with etomoxir, an inhibitor of carnitine palmitoyl transferase (CPT1), the rate limiting
262 enzyme in FAO, was sufficient to abrogate Treg development, suggesting that FAO is essential for
263 Treg development [55].

264 Interestingly, it has recently been demonstrated that the increase in FAO in memory CD8⁺ T is
265 surprisingly the direct result of *de novo* FAS, rather than uptake of fatty acids from the extracellular
266 environment [57]. After observing no increase in extracellular fatty acid uptake, the authors showed
267 that extracellular glucose fuels mitochondrial fatty acid oxidation and oxidative phosphorylation
268 (OXPHOS) indicating that fatty acids are synthesised for subsequent oxidation. Upon treatment with
269 a fatty acid synthase inhibitor, memory T cell death increased suggesting fatty acid synthesis is
270 necessary for their survival. Memory T cells lack typical fatty acid storage droplets; instead,
271 lysosomal acid lipase (LAL) activity plays a role in non-classical fatty acid storage. LAL is required for
272 lipolysis of stored fatty acids to generate available fatty acids for oxidation and necessary for
273 memory T cell survival. These data support the phenomenon known as fatty acid “futile cycling”
274 whereby intracellular fatty acids are catabolized rather than acquired from extracellular sources, for
275 use in the mitochondria for fatty acid oxidation. With no net gain of ATP, this cycling of fatty acids is
276 bio-energetically redundant. However, it has been suggested that fatty acid cycling in memory T cells
277 may provide a mechanism to maintain their survival and, sustaining their glycolytic and
278 mitochondrial metabolism, may enable rapid recall responses after antigen recognition.

279 Extracellular signalling by IL-7 and IL-15 has been shown to impact on T cell development by
280 affecting FAO [58, 59] (Figure 4). The cytokine IL-15, which is critical for the development and
281 maintenance of CD8⁺ memory cells, enhanced the expression of the rate-limiting FAO enzyme CPT1,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

282 and thus FAO. Importantly, blocking CPT1 with etomoxir impaired the mitochondrial spare
283 respiratory capacity (see Glossary) and survival of CD8⁺ memory T cells. Conversely, over-expression
284 of CPT1 increased the formation of CD8⁺ memory T cells following infection [58]. IL-7 is known to
285 control CD8⁺ memory T cell longevity and homeostasis [60, 61]. Recent findings demonstrate a new
286 pathway in which IL-7 promotes survival via glycerol import, triglyceride synthesis and storage.
287 Triglycerides are synthesized combining glycerol-3-phosphate and Acyl-CoAs (free fatty acids
288 activated with a Coenzyme-A moiety), thus the amount of glycerol affects triglyceride synthesis. In
289 this study IL-7 was shown to induce expression of the glycerol channel aquaporin 9 (AQP9), which
290 was required for long term survival of CD8⁺ memory cells. AQP9 deficiency resulted in impaired
291 glycerol import, and thus esterification of fatty acids and reduced triglyceride synthesis and storage.
292 These defects were rescued by ectopic expression of triglyceride synthases, which restored lipid
293 stores and CD8⁺ memory T cells [59].

294 Acyl-CoA is the main intermediate metabolite of lipid metabolism within the cell. FAO
295 involves the sequential removal of 2-carbon units from a fatty acyl-CoA molecule to yield acetyl-CoA,
296 which can be directly shuttled into the TCA cycle. While intermediate products of glycolysis and the
297 TCA cycle have been shown to have active signalling roles, little research has been done into
298 whether FAO metabolites may have direct effects on the cell fate decision of T cells. However, a
299 recent paper has shown that long chain acyl-CoAs, which are the activated form of free fatty acids
300 and represent the pre-step reaction for β -oxidation, can act as positive modulators of ion channels
301 and exchangers [3]. Specifically, long chain acyl-CoAs were shown to be potent activators of TRPV1
302 cation channels independently of Ca²⁺, and increasing the level of long chain acyl-CoAs in intact
303 Jurkat T cells leads to a significant increase in agonist-induced Ca²⁺ levels. This novel mechanism
304 indicates that long chain acyl-CoAs could play an active role in T cell functions under both
305 physiological and pathophysiological conditions that alter fatty acid transport and metabolism.

306 Acetyl-CoA, the end product of FAO, has also been implicated to have roles beyond the TCA
307 cycle, as it can also act as a substrate for post-translational modifications such as acetylation [62].

308 One potential mechanism is through histone acetylation, which is known to be important for
309 promoting gene transcription. In the context of immune cells, CD8⁺ T cells histone acetylation occurs
310 at specific loci and may be involved in determining the decision between memory and short-lived
311 effector cell fate [63]. Similarly, different histone acetylation patterns have been shown in CD4⁺
312 effector T cells compared to CD4⁺ Tregs. Specifically, in Tregs there is increased acetylation of the
313 Foxp3 locus [64], whereas in T effector cells the IL-13, IL-15 and IL-4 loci have all been shown to have
314 increased acetylation induced by IL-4 [65].

315

316 **Concluding remarks**

317

318 The discovery of extra-metabolic functions of metabolic enzymes (referred to as moon-
319 lighting) has been the first evidence that metabolism and its players have a role in the regulation of
320 signalling pathways inside cells. Here, we have described how a similar concept applies to
321 metabolites, which for decades were considered to be only the building blocks of biomasses. The
322 observation that intermediates and end products of the main metabolic pathways can desert their
323 metabolic roles to function, in certain circumstances, as transduction signals shows how these
324 molecules can play an active and crucial role in regulating some of the most important biological
325 processes. We currently have evidence that some metabolites play roles in the immune and
326 inflammatory responses, and influence cytokine production, proliferation and angiogenesis, both in
327 physiology and pathology. It remains to be established if other metabolites might display similar
328 functions.

329 In this new scenario, the accumulation or the depletion of specific metabolites does not
330 represent just a metabolic adaptation or a choice merely dictated by energy demand; it is rather an
331 elected form of signalling-mediated regulation of biological processes. The loss of this intrinsic
332 regulation is associated with several pathological conditions, and this might explain the current
333 efforts to target metabolic pathways for therapeutic purpose. In doing so, we need to bear in mind

1
2
3
4
5 334 that some processes, such as ROS production, are necessary but must be tightly regulated to
6
7
8
9
10 335 maintain homeostasis; hence in some cases mild intervention could be safer and even more
11
12
13
14
15 336 beneficial than blunt blockade.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

337 **ACKNOWLEDGEMENTS**

338

339 This work is supported by the British Heart Foundation Fellowship FS/12/38/29640 to CM
340 and forms part of the research themes contributing to the translational research portfolio of Barts
341 and the London Cardiovascular Biomedical Research Unit, which is supported and funded by the
342 National Institutes of Health Research. RH is supported by a PhD studentship from the Medical
343 Research Council, UK. DC is supported by a Fellowship from the Istituto Pasteur, Fondazione Cenci-
344 Bolognetti. CEM is supported by a PhD studentship from the British Heart Foundation.

345

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

346 **BOX1 - Basics of TCA cycle, FAO and ETC/RET**

347

348 **TCA cycle**

349 The tricarboxylic acid (TCA) cycle, also known as citric acid cycle or Krebs Cycle, is a series of
350 biochemical reactions occurring into the mitochondrion that provide energy and reducing
351 equivalents through the complete oxidation of acetate, in form of acetyl-CoA, produced from the
352 breakdown of sugars, lipids and amino-acids (Figure 1).

354 **FAO**

355 Fatty acids are an alternative source of fuel for cells yielding large amounts of ATP during
356 their oxidation. This catabolic process occurs in the mitochondria to generate acetyl-CoA, which
357 directly enters into the TCA cycle (Figure 1).

359 **ETC**

360 The mitochondrial electron transport chain (ETC) is a series of protein complexes embedded into the
361 inner mitochondrial membrane responsible for the transfer of electrons from donors to acceptors
362 via redox reactions. The transfer of electrons through the chain is coupled to the pumping of protons
363 into the intermembrane space. This proton gradient provides the proton-motive force necessary for
364 the generation of energy in the form of ATP. In eukaryotes, ETC is composed of 4 complexes:
365 complex I or NADH dehydrogenase, which oxidizes NADH and transfers electrons to ubiquinone Q
366 (thus turned to ubiquinol QH₂) while pumping four protons into the intermembrane space; complex
367 II or succinate dehydrogenase, which oxidizes succinate to fumarate and transfers electrons to
368 ubiquinone; complex III or cytochrome c oxidoreductase, which re-oxidizes ubiquinol to ubiquinone
369 while reducing cytochrome c and pumping two protons across the membrane; and complex IV or
370 cytochrome c oxidase, which oxidizes cytochrome c passing electrons to the final acceptor of the
371 chain, molecular oxygen O₂, generating water and pumping four protons across the membrane.

372 Finally, ATP synthase utilizes the energy stored into the protons gradient to phosphorylate ADP to

373 ATP. Complex I and II represent two independent entry points to the ETC.

374

375 **RET**

376 Reverse electron transfer (RET) is the flow of electrons from ubiquinone to NAD^+ catalysed by

377 complex I in the presence of a reduced pool of QH_2 and a high proton gradient forcing electrons

378 backward from QH_2 into complex I, which leads to the production of superoxide [66, 67].

379

380

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

381 **GLOSSARY**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

382 **REDOX STATE**

383 The cellular redox state is often described as the balance of **reduced** and **oxidized** glutathione
384 (GSH/GSSG), Nicotinamidedinuclotide (NAD^+/NADH) and Nicotinamidedinuclotide-phosphate
385 ($\text{NADP}^+/\text{NADPH}$). These redox couples are central mediators for catabolic and anabolic reactions
386 acting as cofactors and regulators for enzymes, scavengers for reactive oxygen species or substrates
387 for the mitochondrial electron transport chain.

388 **FUMARATE HYDRATASE (FH):**

389 The TCA cycle enzyme responsible for the conversion of fumarate to malate.

390 **SPARE RESPIRATORY CAPACITY:**

391 The extra capacity available in cell to produce energy via mitochondrial respiration.

394 **FIGURE LEGENDS**

395

396 **Figure 1 – Metabolic pathways and regulatory intermediates of metabolism.** The main cellular
397 catabolic pathways (glycolysis: blue; tricarboxylic acid (TCA) cycle: red; fatty acid oxidation (FAO):
398 green) not only produce ATP, but also metabolic intermediates, such as lactate, acetyl-CoA and
399 succinate, highlighted in colour. These are substrates for anabolic processes including lipid and
400 nucleotide synthesis, but can also act as regulatory signalling molecules.

401

402 **Figure 2, Key Figure – Lactate-mediated signalling pathways and their biological outcomes.**

403 Extracellular lactate (left side of the figure) has staggering functional effects on several cell types,
404 including production of pro- and anti-inflammatory mediators by T cells and macrophages (M ϕ), or
405 migratory changes and metabolic adaptation in T cells, endothelial cells (EC) and neurons.
406 Intracellularly (right side of the figure), lactate can directly bind to proteins (i.e. NDRG3), influence
407 the redox state via the lactate dehydrogenase (LDH) reaction, stabilize Hif-1 α , induce reactive
408 oxygen species (ROS) and act as an inhibitor of glucose breakdown. The occurrence of these effects
409 might depend on the investigated cell type.

410

411 **Figure 3 – Succinate signalling and its biological effects.** Succinate exerts several biological

412 responses. By stabilizing Hif-1 α , it promotes proliferation, angiogenesis and cytokine production.
413 Succinate can also regulate proteins activity via succinylation. During ischaemia, fumarate
414 accumulates through the malate-aspartate shuttle (MAS) and the purine nucleotide cycle (PNC) and
415 is converted into succinate by succinate dehydrogenase reversal (SDH); during reperfusion, the rapid
416 re-oxidation of succinate to fumarate by SDH leads to the production of mitochondrial reactive
417 oxygen species (mROS) responsible for tissue damage. Furthermore, succinate in the extracellular
418 microenvironment can signal through its receptor (GPR91), sustaining cytokine production and
419 migration of dendritic cells (DC). TCA, tricarboxylic acid cycle; AMP, adenosine monophosphate; IMP,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 420 inosine monophosphate; PHD, prolyl hydroxylases; GABA, γ -aminobutyric acid; IR, ischaemia-
3 reperfusion.

4
5 422

6
7 423 **Figure 4 – Fatty acids oxidation and its role in signalling.** FAO has been shown to be necessary for
8
9 424 CD8+ memory T cells survival and CD4+ regulatory T cells induction. Moreover, upregulation of
10
11 425 glycerol transporter AQP9 by cytokines is important to increase triglycerides synthesis and thus FAO.
12
13 426 The futile cycling of lipolysis and subsequent FAO seems to be important for memory T cell survival.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

427 **REFERENCES**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462

1 Kesarwani, P., *et al.* (2013) Redox regulation of T-cell function: from molecular mechanisms to significance in human health and disease. *Antioxidants & redox signaling* 18, 1497-1534

2 Tannahill, G.M., *et al.* (2013) Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. *Nature* 496, 238-242

3 Yu, Y., *et al.* (2014) Intracellular long-chain acyl CoAs activate TRPV1 channels. *PLoS one* 9, e96597

4 Cai, T.Q., *et al.* (2008) Role of GPR81 in lactate-mediated reduction of adipose lipolysis. *Biochem Biophys Res Commun* 377, 987-991

5 He, W., *et al.* (2004) Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. *Nature* 429, 188-193

6 Kompanje, E.J., *et al.* (2007) The first demonstration of lactic acid in human blood in shock by Johann Joseph Scherer (1814-1869) in January 1843. *Intensive Care Med* 33, 1967-1971

7 Cornell, N.W., *et al.* (1973) Acceleration of gluconeogenesis from lactate by lysine (Short Communication). *The Biochemical journal* 134, 671-672

8 Pellerin, L. and Magistretti, P.J. (1994) Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. *Proceedings of the National Academy of Sciences of the United States of America* 91, 10625-10629

9 Hashimoto, T., *et al.* (2007) Lactate sensitive transcription factor network in L6 cells: activation of MCT1 and mitochondrial biogenesis. *FASEB J* 21, 2602-2612

10 Yang, J., *et al.* (2014) Lactate promotes plasticity gene expression by potentiating NMDA signaling in neurons. *Proceedings of the National Academy of Sciences of the United States of America* 111, 12228-12233

11 Beckert, S., *et al.* (2005) Experimental ischemic wounds: correlation of cell proliferation and insulin-like growth factor I expression and its modification by different local IGF-I release systems. *Wound Repair Regen* 13, 278-283

12 Baumann, F., *et al.* (2009) Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2. *Neuro Oncol* 11, 368-380

13 Bonuccelli, G., *et al.* (2010) Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. *Cell Cycle* 9, 3506-3514

14 Colegio, O.R., *et al.* (2014) Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. *Nature* 513, 559-563

15 Haas, R., *et al.* (2015) Lactate Regulates Metabolic and Pro-inflammatory Circuits in Control of T Cell Migration and Effector Functions. *PLoS biology* 13, e1002202

16 Su, S., *et al.* (2014) A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. *Cancer cell* 25, 605-620

463 17 Halestrap, A.P. (2012) The monocarboxylate transporter family--Structure and functional
1 464 characterization. *IUBMB Life* 64, 1-9
2
3 465 18 Srinivas, S.R., *et al.* (2005) Cloning and functional identification of slc5a12 as a sodium-coupled
4 466 low-affinity transporter for monocarboxylates (SMCT2). *The Biochemical journal* 392, 655-664
5
6
7 467 19 Morris, M.E. and Felmlee, M.A. (2008) Overview of the proton-coupled MCT (SLC16A) family of
8 468 transporters: characterization, function and role in the transport of the drug of abuse gamma-
9 469 hydroxybutyric acid. *AAPS J* 10, 311-321
10
11 470 20 Hirschhaeuser, F., *et al.* (2011) Lactate: a metabolic key player in cancer. *Cancer research* 71,
12 471 6921-6925
13
14
15 472 21 Sonveaux, P., *et al.* (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells
16 473 in mice. *J Clin Invest* 118, 3930-3942
17
18 474 22 Sonveaux, P., *et al.* (2012) Targeting the lactate transporter MCT1 in endothelial cells inhibits
19 475 lactate-induced HIF-1 activation and tumor angiogenesis. *PloS one* 7, e33418
20
21 476 23 Vegran, F., *et al.* (2011) Lactate influx through the endothelial cell monocarboxylate transporter
22 477 MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis. *Cancer research* 71,
23 478 2550-2560
24
25
26 479 24 Lee, D.C., *et al.* (2015) A lactate-induced response to hypoxia. *Cell* 161, 595-609
27
28 480 25 Leite, T.C., *et al.* (2011) Lactate downregulates the glycolytic enzymes hexokinase and
29 481 phosphofructokinase in diverse tissues from mice. *FEBS Lett* 585, 92-98
30
31
32 482 26 Fischer, K., *et al.* (2007) Inhibitory effect of tumor cell-derived lactic acid on human T cells. *Blood*
33 483 109, 3812-3819
34
35 484 27 Lee, D.K., *et al.* (2001) Discovery and mapping of ten novel G protein-coupled receptor genes.
36 485 *Gene* 275, 83-91
37
38
39 486 28 Ge, H., *et al.* (2008) Elucidation of signaling and functional activities of an orphan GPCR, GPR81. *J*
40 487 *Lipid Res* 49, 797-803
41
42 488 29 Liu, C., *et al.* (2009) Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-
43 489 coupled receptor, GPR81. *The Journal of biological chemistry* 284, 2811-2822
44
45 490 30 Ahmed, K., *et al.* (2010) An autocrine lactate loop mediates insulin-dependent inhibition of
46 491 lipolysis through GPR81. *Cell Metab* 11, 311-319
47
48
49 492 31 Roland, C.L., *et al.* (2014) Cell surface lactate receptor GPR81 is crucial for cancer cell survival.
50 493 *Cancer research* 74, 5301-5310
51
52 494 32 Staubert, C., *et al.* (2015) Hydroxycarboxylic acid receptors are essential for breast cancer cells to
53 495 control their lipid/fatty acid metabolism. *Oncotarget* 6, 19706-19720
54
55
56 496 33 Shen, Z., *et al.* (2015) Inhibition of G protein-coupled receptor 81 (GPR81) protects against
57 497 ischemic brain injury. *CNS Neurosci Ther* 21, 271-279
58
59
60
61
62
63
64
65

498 34 Brooks, G.A., *et al.* (1999) Role of mitochondrial lactate dehydrogenase and lactate oxidation in
1 499 the intracellular lactate shuttle. *Proceedings of the National Academy of Sciences of the United*
2 500 *States of America* 96, 1129-1134
3
4 501 35 Hashimoto, T., *et al.* (2006) Colocalization of MCT1, CD147, and LDH in mitochondrial inner
5 502 membrane of L6 muscle cells: evidence of a mitochondrial lactate oxidation complex. *Am J Physiol*
6 503 *Endocrinol Metab* 290, E1237-1244
7
8
9 504 36 Schueren, F., *et al.* (2014) Peroxisomal lactate dehydrogenase is generated by translational
10 505 readthrough in mammals. *Elife* 3, e03640
11
12 506 37 Passarella, S., *et al.* (2014) The mitochondrial L-lactate dehydrogenase affair. *Frontiers in*
13 507 *neuroscience* 8, 407
14
15
16 508 38 Medina, R.A., *et al.* (2002) Lactate-induced translocation of GLUT1 and GLUT4 is not mediated by
17 509 the phosphatidyl-inositol-3-kinase pathway in the rat heart. *Basic Res Cardiol* 97, 168-176
18
19 510 39 Infantino, V., *et al.* (2011) The mitochondrial citrate carrier: a new player in inflammation. *The*
20 511 *Biochemical journal* 438, 433-436
21
22
23 512 40 Frezza, C., *et al.* (2011) Haem oxygenase is synthetically lethal with the tumour suppressor
24 513 fumarate hydratase. *Nature* 477, 225-228
25
26 514 41 Sullivan, L.B., *et al.* (2013) The proto-oncometabolite fumarate binds glutathione to amplify ROS-
27 515 dependent signaling. *Molecular cell* 51, 236-248
28
29
30 516 42 Clark, G.R., *et al.* (2014) Germline FH mutations presenting with pheochromocytoma. *The Journal*
31 517 *of clinical endocrinology and metabolism* 99, E2046-2050
32
33 518 43 Tomlinson, I.P., *et al.* (2002) Germline mutations in FH predispose to dominantly inherited uterine
34 519 fibroids, skin leiomyomata and papillary renal cell cancer. *Nature genetics* 30, 406-410
35
36 520 44 Koivunen, P., *et al.* (2007) Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid
37 521 cycle intermediates: possible links between cell metabolism and stabilization of HIF. *The Journal of*
38 522 *biological chemistry* 282, 4524-4532
39
40
41 523 45 Yeung, F., *et al.* (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the
42 524 SIRT1 deacetylase. *The EMBO journal* 23, 2369-2380
43
44 525 46 Zhang, R., *et al.* (2010) SIRT1 suppresses activator protein-1 transcriptional activity and
45 526 cyclooxygenase-2 expression in macrophages. *The Journal of biological chemistry* 285, 7097-7110
46
47
48 527 47 Jang, S.Y., *et al.* (2012) Nicotinamide-induced mitophagy: event mediated by high NAD⁺/NADH
49 528 ratio and SIRT1 protein activation. *The Journal of biological chemistry* 287, 19304-19314
50
51 529 48 Pugh, C.W. and Ratcliffe, P.J. (2003) Regulation of angiogenesis by hypoxia: role of the HIF
52 530 system. *Nature medicine* 9, 677-684
53
54
55 531 49 Selak, M.A., *et al.* (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-
56 532 alpha prolyl hydroxylase. *Cancer cell* 7, 77-85
57
58 533 50 Jha, A.K., *et al.* (2015) Network integration of parallel metabolic and transcriptional data reveals
59 534 metabolic modules that regulate macrophage polarization. *Immunity* 42, 419-430
60
61
62
63
64
65

535 51 Michelucci, A., *et al.* (2013) Immune-responsive gene 1 protein links metabolism to immunity by
1 536 catalyzing itaconic acid production. *Proceedings of the National Academy of Sciences of the United*
2 537 *States of America* 110, 7820-7825
3
4 538 52 Chouchani, E.T., *et al.* (2014) Ischaemic accumulation of succinate controls reperfusion injury
5 539 through mitochondrial ROS. *Nature* 515, 431-435
6
7
8 540 53 Rubic, T., *et al.* (2008) Triggering the succinate receptor GPR91 on dendritic cells enhances
9 541 immunity. *Nature immunology* 9, 1261-1269
10
11 542 54 Pearce, E.L., *et al.* (2009) Enhancing CD8 T-cell memory by modulating fatty acid metabolism.
12 543 *Nature* 460, 103-107
13
14 544 55 Michalek, R.D., *et al.* (2011) Cutting edge: distinct glycolytic and lipid oxidative metabolic
15 545 programs are essential for effector and regulatory CD4+ T cell subsets. *Journal of immunology*
16 546 (*Baltimore, Md. : 1950*) 186, 3299-3303
17
18
19 547 56 Berod, L., *et al.* (2014) De novo fatty acid synthesis controls the fate between regulatory T and T
20 548 helper 17 cells. *Nature medicine* 20, 1327-1333
21
22
23 549 57 O'Sullivan, D., *et al.* (2014) Memory CD8(+) T cells use cell-intrinsic lipolysis to support the
24 550 metabolic programming necessary for development. *Immunity* 41, 75-88
25
26 551 58 van der Windt, G.J., *et al.* (2012) Mitochondrial respiratory capacity is a critical regulator of CD8+
27 552 T cell memory development. *Immunity* 36, 68-78
28
29
30 553 59 Cui, G., *et al.* (2015) IL-7-Induced Glycerol Transport and TAG Synthesis Promotes Memory CD8+ T
31 554 Cell Longevity. *Cell* 161, 750-761
32
33 555 60 Schluns, K.S., *et al.* (2000) Interleukin-7 mediates the homeostasis of naive and memory CD8 T
34 556 cells in vivo. *Nature immunology* 1, 426-432
35
36 557 61 Kaech, S.M., *et al.* (2003) Selective expression of the interleukin 7 receptor identifies effector CD8
37 558 T cells that give rise to long-lived memory cells. *Nature immunology* 4, 1191-1198
38
39
40 559 62 Fan, J., *et al.* (2015) Metabolic regulation of histone post-translational modifications. *ACS*
41 560 *chemical biology* 10, 95-108
42
43 561 63 Shin, H.M., *et al.* (2013) Epigenetic modifications induced by Blimp-1 Regulate CD8(+) T cell
44 562 memory progression during acute virus infection. *Immunity* 39, 661-675
45
46
47 563 64 Floess, S., *et al.* (2007) Epigenetic control of the foxp3 locus in regulatory T cells. *PLoS biology* 5,
48 564 e38
49
50 565 65 Zhou, W., *et al.* (2004) Long-range histone acetylation of the *lfn* gene is an essential feature of T
51 566 cell differentiation. *Proceedings of the National Academy of Sciences of the United States of America*
52 567 101, 2440-2445
53
54
55 568 66 Murphy, M.P. (2009) How mitochondria produce reactive oxygen species. *The Biochemical*
56 569 *journal* 417, 1-13
57
58
59
60
61
62
63
64
65

570 67 Pryde, K.R. and Hirst, J. (2011) Superoxide is produced by the reduced flavin in mitochondrial
1 571 complex I: a single, unified mechanism that applies during both forward and reverse electron
2 572 transfer. *The Journal of biological chemistry* 286, 18056-18065
3
4 573
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

OUTSTANDING QUESTIONS BOX

- Lactate has two primary means of relaying signals into the cell, receptor- and transporter mediated, and depending on the cell type has several possible outcomes. The downstream pathways still need to be worked out and might illuminate new knowledge in the near future.
- Besides succinate, other metabolites of the TCA cycle might be directly regulating immune cell functions but this is yet to be fully investigated.
- Unlike glycolysis and the TCA cycle, whose intermediates have been shown to play important roles in determining specific T cell fates and functional specifications, the same has yet to be defined for the cellular metabolism of fatty acids.









